DK13788A - Fremgangsmaade til fremstilling af et polypeptid - Google Patents

Fremgangsmaade til fremstilling af et polypeptid

Info

Publication number
DK13788A
DK13788A DK013788A DK13788A DK13788A DK 13788 A DK13788 A DK 13788A DK 013788 A DK013788 A DK 013788A DK 13788 A DK13788 A DK 13788A DK 13788 A DK13788 A DK 13788A
Authority
DK
Denmark
Prior art keywords
pct
polypeptide
secretion sequence
terminal secretion
preparing
Prior art date
Application number
DK013788A
Other languages
Danish (da)
English (en)
Other versions
DK13788D0 (da
Inventor
Ian Barry Holland
Nigel Mackman
Jean-Marc Nicaud
Original Assignee
Ian Barry Holland
Nigel Mackman
Nicaud Jean Marc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ian Barry Holland, Nigel Mackman, Nicaud Jean Marc filed Critical Ian Barry Holland
Publication of DK13788D0 publication Critical patent/DK13788D0/da
Publication of DK13788A publication Critical patent/DK13788A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK013788A 1986-05-15 1988-01-13 Fremgangsmaade til fremstilling af et polypeptid DK13788A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868611832A GB8611832D0 (en) 1986-05-15 1986-05-15 Polypeptide
PCT/GB1987/000331 WO1987006953A1 (fr) 1986-05-15 1987-05-14 Procede de production d'un polypeptide

Publications (2)

Publication Number Publication Date
DK13788D0 DK13788D0 (da) 1988-01-13
DK13788A true DK13788A (da) 1988-03-15

Family

ID=10597902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK013788A DK13788A (da) 1986-05-15 1988-01-13 Fremgangsmaade til fremstilling af et polypeptid

Country Status (9)

Country Link
US (1) US5143830A (fr)
EP (1) EP0267224B1 (fr)
JP (1) JPS63503274A (fr)
AT (1) ATE80660T1 (fr)
AU (1) AU600949B2 (fr)
DE (1) DE3781765T2 (fr)
DK (1) DK13788A (fr)
GB (2) GB8611832D0 (fr)
WO (1) WO1987006953A1 (fr)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
US5037743A (en) * 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6210948B1 (en) 1992-06-09 2001-04-03 The University Of British Columbia Expression and secretion of heterologous polypeptides from caulobacter
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US6057091A (en) * 1994-12-02 2000-05-02 The Johns Hopkins University School Of Medicine Method of identifying compounds affecting hedgehog cholesterol transfer
US6214794B1 (en) 1994-12-02 2001-04-10 The Johns Hopkins University School Of Medicine Method of using hedgehog polypeptides to regulate neuronal cell growth
US6911528B1 (en) 1994-12-02 2005-06-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6281332B1 (en) * 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
JPH1075774A (ja) * 1996-05-31 1998-03-24 Akzo Nobel Nv パスツレラ科の弱毒化ｒｔｘ産生細菌
DK1632574T3 (da) 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
BR9808059A (pt) 1997-03-24 2000-03-08 Zimogenetics Inc Molécula de plinucleotìdeo isolada codificando um polipeptìdeo, polinucleotìdeo, vetor de expressão, célula cultivada, polipeptìdeo isolado, composição farmacêutica, anticorpo, processos para produzir polipeptìdeo zsig33, e, para estimular a motilidde gástrica
KR20010052736A (ko) 1998-06-10 2001-06-25 피아 스타르 신규한 만난나제
EP2105446B1 (fr) 1998-09-23 2013-08-14 ZymoGenetics, Inc. Récepteur de cytokine zalpha11
CA2354325C (fr) 1998-12-07 2011-08-16 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance
WO2000040716A2 (fr) 1999-01-07 2000-07-13 Zymogenetics, Inc. RECEPTEURS SOLUBLES BR43x2 ET PROCEDES D'UTILISATION
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CA2261186A1 (fr) 1999-02-19 2000-08-19 University Of British Columbia Extraction et secretion de polypeptides heterologues du caulobacter d'eau douce
EP1165791B1 (fr) 1999-03-09 2007-10-31 ZymoGenetics, Inc. Cytokine humaine ligand du recepteur zalpha et ses utilisations
US6664386B1 (en) 1999-04-08 2003-12-16 The Research Foundation Of State University Of New York System for efficient secretion of recombinant proteins
IL147336A0 (en) 1999-07-07 2002-08-14 Zymogenetics Inc Human cytokine receptor
AU2136601A (en) * 1999-12-17 2001-06-25 University Of Guelph Modified leukotoxin gene and protein
CA2395369C (fr) 1999-12-23 2014-07-08 Zymogenetics, Inc. Cytokine zcyto18
WO2001077171A2 (fr) 2000-04-05 2001-10-18 Zymogenetics, Inc. Recepteurs de cytokines zalpha11 solubles
CA2412239C (fr) 2000-06-26 2013-05-28 Zymogenetics, Inc. Zcytor17, recepteur de la cytokine
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7795002B2 (en) * 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
WO2002002627A2 (fr) 2000-06-30 2002-01-10 Zymogenetics, Inc. Proteine zcyto21de type interferon
EP1736545A3 (fr) 2000-08-08 2007-03-28 ZymoGenetics, Inc. Récepteurs de cytokines zcytor 11 solubles
KR100447530B1 (ko) * 2001-08-14 2004-09-08 한국과학기술원 ＯｍｐＦ를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
EP1446489B1 (fr) 2001-10-15 2012-01-18 EnGeneIC Molecular Delivery Pty Ltd. Mini-cellules entieres utilisees en tant que vecteurs pour le transfert d'adn et la therapie genique in vitro et in vivo
US6929932B2 (en) 2001-11-05 2005-08-16 Zymogenetics, Inc. IL-21 antagonists
AU2002359721A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
DK1476541T3 (da) 2002-01-18 2008-11-03 Zymogenetics Inc Cytokin (zcytor17-ligand)
AU2003280410B8 (en) 2002-01-18 2009-04-23 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
EP1497415B1 (fr) 2002-04-19 2010-12-29 ZymoGenetics, L.L.C. Methodes d'identification ou modulation de l'interaction d'un recepteur de cytokine et son ligand
PT1531850E (pt) 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
WO2004078965A1 (fr) * 2003-03-05 2004-09-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Procede de production d'une proteine etrangere dans escherichia coli
US20040241677A1 (en) * 2003-05-29 2004-12-02 Lin Jeffrey S Techniques for automated diagnosis of cell-borne anomalies with digital optical microscope
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
ES2303132T3 (es) 2003-08-07 2008-08-01 Zymogenetics, Inc. Preparaciones homogeneas de il-29.
EP2087905A2 (fr) 2003-08-08 2009-08-12 Novo Nordisk A/S Interleukine-20 dans le traitement et le diagnostic des états associés à la neovascularisation
DE602004029173D1 (de) 2003-10-10 2010-10-28 Novo Nordisk As Il-21-derivate
EP2641611A3 (fr) 2003-10-17 2013-12-18 Novo Nordisk A/S Thérapie combinée
CA2549840C (fr) 2003-12-09 2012-03-20 Engeneic Molecular Delivery Pty Ltd. Administration ciblee de genes a des cellules mammiferes non phagocytaires par l'intermediaire de minicellules intactes derivees de bacteries
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
WO2006012644A2 (fr) 2004-07-29 2006-02-02 Zymogenetics, Inc. Utilisation des molecules il-28 et il-29 pour traiter le cancer et les troubles autoimmuns
EP2166104B1 (fr) 2004-08-02 2013-06-12 BASF Plant Science GmbH Procédé d'isolation de séquence de terminaison de transcription
NZ553910A (en) 2004-08-26 2009-05-31 Engeneic Molecular Delivery Pty Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells
AU2006212807A1 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
US7393667B2 (en) * 2005-05-31 2008-07-01 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
EP1922079A2 (fr) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
JP2009507777A (ja) * 2005-08-09 2009-02-26 ザイモジェネティクス，インコーポレイティド ＴＡＣＩ−Ｉｇ融合分子を用いたＢ細胞性腫瘍の処置方法
US8784812B2 (en) * 2006-05-15 2014-07-22 Zymogenetics, Inc. Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
DK2712618T3 (en) 2006-06-23 2017-01-30 Engeneic Molecular Delivery Pty Ltd Targeted administration of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells using intact killed bacterial cells
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
AU2008257448B9 (en) * 2007-05-31 2013-07-11 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
ES2629440T5 (es) 2007-10-04 2020-11-20 Zymogenetics Inc zB7H6 miembro de la familia B7 y composiciones y métodos relacionados
US8859230B2 (en) 2007-11-21 2014-10-14 Roskilde Universitet Polypeptides comprising an ice-binding activity
WO2009080054A1 (fr) * 2007-12-21 2009-07-02 Ifxa A/S Inhibiteur de protéases
WO2009092806A2 (fr) * 2008-01-25 2009-07-30 Aarhus Universitet Inhibition de l'exosite sélectif de l'activité de papp-a contre igfbp-4
JP5425180B2 (ja) 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
CA2733425A1 (fr) 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccins contre clostridium difficile, et procedes d'utilisation
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2011156356A1 (fr) 2010-06-09 2011-12-15 Zymogenetics, Inc. Protéines de fusion vstm3 dimères et compositions et procédés connexes
EP2670426B1 (fr) 2011-01-31 2017-05-10 The General Hospital Corporation Molécules trail multimodales et leurs utilisations en thérapies cellulaires
EP2583975A1 (fr) * 2011-10-21 2013-04-24 Heinrich-Heine-Universität Düsseldorf Agents et procédés pour l'expression et la sécrétion de peptides et de protéines
JP2015509005A (ja) 2012-02-01 2015-03-26 シンセティック ジェノミクス インコーポレーテッド エラーを最少限に抑える核酸分子の合成のための材料及び方法
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
KR102141259B1 (ko) 2012-09-04 2020-08-05 셀렉티스 멀티―체인 키메라 항원 수용체 및 그것의 용도들
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2990485B1 (fr) 2013-04-25 2019-09-11 Kaneka Corporation Gene de chaine fd ou gene de chaine l chacun apte a augmenter la quantite de secretion d'anticorps de type fab
CN105431532B (zh) 2013-05-13 2021-04-06 瑟勒提斯公司 Cd19特异性嵌合抗原受体及其用途
WO2014202089A2 (fr) 2013-06-18 2014-12-24 Roskilde Universitet Variants de polypeptides antigel
WO2015089280A1 (fr) 2013-12-11 2015-06-18 The General Hospital Corporation Virus herpes simplex oncolytique délivré par une cellule souche et procédés de traitement de tumeurs du cerveau
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
MX370272B (es) 2014-03-19 2019-12-09 Cellectis Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
US20170051037A1 (en) 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
ES2876925T3 (es) 2014-07-29 2021-11-15 Cellectis Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer
EP3194432B1 (fr) 2014-07-31 2019-04-10 Cellectis Recepteur d'antigene chimere a chaines multiples specifique de ror1
CA2959694C (fr) 2014-09-04 2023-11-21 Cellectis Recepteurs d'antigenes chimeriques specifiques de la glycoproteine trophoblastique (5t4, tpbg) utilises pour l'immunotherapie du cancer
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11014989B2 (en) 2015-01-26 2021-05-25 Cellectis Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
BR112017019914A2 (pt) 2015-04-13 2018-06-19 Pfizer receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
WO2017044424A1 (fr) 2015-09-08 2017-03-16 Theripion, Inc. Polypeptides de fusion apoa-1 ainsi que compositions et procédés associés
KR102479606B1 (ko) 2016-01-21 2022-12-21 화이자 인코포레이티드 상피 성장 인자 수용체 변이체 iii을 표적화하는 키메라 항원 수용체
US11485976B2 (en) 2016-10-06 2022-11-01 Engeneic Molecular Delivery Pty Ltd Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same
WO2018073394A1 (fr) 2016-10-19 2018-04-26 Cellectis Récepteurs d'antigènes chimériques induisant la mort cellulaire
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018136163A2 (fr) 2016-12-09 2018-07-26 Theripion, Inc. Polypeptides de fusion apoa-1 en tandem
CA3058268A1 (fr) 2017-03-31 2018-10-04 Cellectis Sa Cellules immunitaires modifiees dotees de recepteurs antigeniques chimeriques anti-cd22 universels
AU2018255926B9 (en) 2017-04-19 2023-10-19 Allogene Therapeutics, Inc. Improved T cell compositions and methods
CN110831970A (zh) 2017-06-02 2020-02-21 辉瑞公司 靶向flt3的嵌合抗原受体
JP2020530277A (ja) 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ 反復投与のための細胞免疫療法
CA3070272A1 (fr) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Proteines de liaison a l'antigene se liant a 5t4 et 4-1bb, compositions et procedes associes
WO2019072824A1 (fr) 2017-10-09 2019-04-18 Cellectis Car anti-cd123 amélioré dans des lymphocytes t immunitaires modifiés universels
EP3703689A1 (fr) 2017-11-01 2020-09-09 Allogene Therapeutics, Inc. Polypeptides de caspase-9 modifiés et leurs procédés d'utilisation
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
CN111801346A (zh) 2017-12-27 2020-10-20 免疫实验室私人有限公司 重组多肽及其使用方法
US10150801B1 (en) 2017-12-27 2018-12-11 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
MX2020008184A (es) 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
CN111936519A (zh) 2018-02-01 2020-11-13 辉瑞公司 对cd70具有特异性的抗体及其用途
MX2020009051A (es) 2018-03-02 2020-12-03 Allogene Therapeutics Inc Receptores de citocina quimericos inducibles.
EP3817767A1 (fr) 2018-07-02 2021-05-12 Cellectis Cellules exprimant des récepteurs d'antigènes chimériques (car) et traitement combiné pour l'immunothérapie de patients atteints de lma récidivante ou réfractaire avec un risque génétique indésirable
US20220009993A1 (en) 2018-11-14 2022-01-13 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for safer and more effective immunotherapies
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
MX2022001882A (es) 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
US10675332B1 (en) 2019-08-26 2020-06-09 Imunami Laboratories Pte. Ltd. Recombinant polypeptides and methods of use thereof
EP4021512A1 (fr) 2019-08-26 2022-07-06 Imunami Laboratories Pte. Ltd. Polypeptides recombinants et leurs méthodes d'utilisation
US20230144204A1 (en) 2020-03-18 2023-05-11 Numaferm Gmbh Fragments of hlya and uses thereof
EP3882260A1 (fr) * 2020-03-18 2021-09-22 NUMAFERM GmbH Fragments de hlya et leurs utilisations
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
JP2023538476A (ja) 2020-06-22 2023-09-08 イミュナミ ラボラトリーズ プライベート リミティド 癌治療における使用のための組換えポリペプチド及び組合せ
AU2021312871A1 (en) 2020-07-21 2023-02-09 Allogene Therapeutics, Inc. Chimeric antigen receptors with enhanced signaling and activities and uses thereof
US20240043868A1 (en) 2020-09-21 2024-02-08 Fundación Pública Andaluza Progreso Y Salud Polynucleotide for physiological expression in t-cells
AU2021390501A1 (en) 2020-12-01 2023-06-29 Aptevo Research And Development Llc Heterodimeric psma and cd3-binding bispecific antibodies
IL303270A (en) 2020-12-21 2023-07-01 Allogene Therapeutics Inc The CD45–GATE vehicle activates a protease
US20220251505A1 (en) 2021-01-29 2022-08-11 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
WO2022178078A1 (fr) 2021-02-19 2022-08-25 Theripion, Inc. Polypeptides de fusion paraoxonase et compositions et méthodes associées
KR20230151518A (ko) 2021-03-04 2023-11-01 알로젠 테라퓨틱스 인코포레이티드 치료 세포를 동종이계 거부반응 및 활성화 유도된 세포 사멸로부터 보호하기 위한 FasL 발현 및 FasR 유전자 녹아웃
EP4308704A1 (fr) 2021-03-18 2024-01-24 NUMAFERM GmbH Protéines de fusion comprenant des séquences de répétition gg
KR20240021826A (ko) 2021-06-15 2024-02-19 알로젠 테라퓨틱스 인코포레이티드 동종이계 car t 세포 지속성을 연장시키기 위한 숙주 cd70+ 동종반응성 세포의 선택적 표적화
US20230346934A1 (en) 2022-03-29 2023-11-02 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
EP4339202A1 (fr) 2022-09-16 2024-03-20 NUMAFERM GmbH Protéines de fusion comprenant des séquences de répétition gg ii

Also Published As

Publication number Publication date
GB8800141D0 (en) 1988-03-02
EP0267224B1 (fr) 1992-09-16
AU600949B2 (en) 1990-08-30
JPS63503274A (ja) 1988-12-02
GB2197324A (fr) 1988-05-18
DE3781765T2 (de) 1993-04-22
GB8611832D0 (en) 1986-06-25
DK13788D0 (da) 1988-01-13
ATE80660T1 (de) 1992-10-15
US5143830A (en) 1992-09-01
DE3781765D1 (de) 1992-10-22
GB2197324B (en) 1990-04-11
EP0267224A1 (fr) 1988-05-18
WO1987006953A1 (fr) 1987-11-19
AU7392387A (en) 1987-12-01

Similar Documents

Publication Publication Date Title
DK13788D0 (da) Fremgangsmaade til fremstilling af et polypeptid
DK0423302T3 (da) Anvendelse af hidtil ukendte DNA-fragmenter som kodende sekvens for et signalpeptid til sekretion af modne proteiner i rekombinant gær, ekspressionskassetter, transformeret gær og tilsvarende fremgangsmåde til fremstilling af proteiner
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
DE69128285D1 (de) Expression rekombinanter polypeptide mit verbesserter möglichkeit zur reinigung
DK219087A (da) Vektorsystem til brug ved transformation af trichoderma, transformerede trichodermastammer og fremgangsmaade til fremstilling af proteiner heri
EP0722461A4 (fr) Expression de polypeptides de fusion transportes hors du cytoplasme sans sequence de tete
DK161152C (da) Polypeptid med egenskaber som human beta-nervevaekstfaktor og fremgangsmaade til fremstilling deraf, dna-isolat omfattende en sekvens som koder for polypeptidet, replicerbar udtrykkelsesvektor for dna-sekvensen, rekombinant vaertscelle transformeret med vektoren, farmaceutisk praeparat indeholdende polypeptidet og fremg. der omfatter anvendelsen af polypeptidet til fremst. af et farmaceutisk praeparat
HU9203449D0 (en) Varied cd44 surfacial proteins, dna sequences coding them, antibodies acting against these proteins as well as application of all these things in diagnostics and therapy
DK645887A (da) Gamma-hesteinterferon, fremgangsmaade til fremstilling af, samt anvendelse af en saadan forbindelse
DE69233463D1 (de) Expression und reinigung von kloniertem humanen alpha-fetoprotein
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
GR3023593T3 (en) Protein structure of the plant toxin gelonin
DE3877035D1 (de) Gentechnologisches verfahren zur herstellung von polypeptiden.
DK35888D0 (da) Fremgangsmaade til fremstilling af rekombinant polypeptider
BR1100940A (pt) Polipeptìdeos puros, sequências adn, molécula adn recombinada, célula hospedeira, processo de manipulação genética para produção de polipeptìdeo, e, uso de um polipeptìdeo
FI861559A (fi) Menetelmä hepatitis B-viruksen pinta-antigeenin PreS1-PreS2-S-proteiinin koodaavan alueen koodaamia proteiineja käsittävän proteiinin valmistamiseksi sekä menetelmässä käytettävät yhdistelmä-DNA-vektorit ja -kontameerit sekä nisäkässolut

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment